{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:53:53Z","timestamp":1770422033896,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170612"],"award-info":[{"award-number":["82170612"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science and Technology Project","award":["2023B01J1007"],"award-info":[{"award-number":["2023B01J1007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Functional cure is the ideal treatment endpoint of chronic hepatitis B (CHB). Currently, only a few patients achieve this with treatment. Host differences must be influential. Solute carrier family 22 member 1 (SLC22A1), encoding organic cation transporter 1, is expressed in the liver and mediates substance transport of hepatocytes. The association between SLC22A1 and CHB has not been determined. Our objective was to elucidate this association.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RNA sequencing was performed to explore the changes caused by hepatitis B virus (HBV) and SLC22A1. Plasma from 200 patients with CHB (120 uncured, 80 cured) completing the pegylated interferon alpha (pegIFN\u03b1)\u2013based treatment was collected at baseline and at 12 and 24 weeks of treatment. SLC22A1 of plasma and liver biopsies in healthy controls and patients with CHB were measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SLC22A1 was down-regulated by HBV, as indicated by comparing SLC22A1 of hepG2 cells with and without HBV and of both liver and plasma in CHB and healthy volunteers. Plasma SLC22A1 rose dynamically in the cured group but not in the uncured group. Plasma SLC22A1 at 24 weeks was predictive of functional cure (area under the receiver operating characteristic curve [AUC], 0.887) and better when combined with hepatitis B surface antigen (HBsAg) at 24 weeks (AUC, 0.925). In vitro experiments regarding overexpression of SLC22A1 in hepG2.2.15 demonstrated that HBsAg and hepatitis B e antigen were inhibited by SLC22A1 through JAK\/STAT pathway activation, consistent with transcriptome sequencing results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HBV inhibits SLC22A1 expression and SLC22A1 suppresses HBV by activating the JAK\/STAT pathway. SLC22A1 is a predictor of the functional cure of CHB with pegIFN\u03b1-based treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf102","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:26:05Z","timestamp":1741119965000},"source":"Crossref","is-referenced-by-count":1,"title":["SLC22A1 Resists Hepatitis B Virus by Activating the JAK\/STAT Pathway and Predicts the Effect of Pegylated Interferon \u03b1\u2013Based Therapy on Chronic Hepatitis B"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8113-1289","authenticated-orcid":false,"given":"Huiying","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1406-019X","authenticated-orcid":false,"given":"Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-0717","authenticated-orcid":false,"given":"Huili","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University , Guangzhou 510062 ,","place":["China"]},{"name":"Department of Rheumatology and Immunology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University , Guangzhou 510062 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoquan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]},{"name":"Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]},{"name":"Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]},{"name":"Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]},{"name":"Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqing","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiliang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]},{"name":"Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University , Guangzhou 510630 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"2025031817142783700_jiaf102-B1","author":"World Health Organization (WHO)"},{"key":"2025031817142783700_jiaf102-B2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2025031817142783700_jiaf102-B4","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","article-title":"Ultra-long-term follow-up of interferon alfa treatment for HBeAg-positive chronic hepatitis B virus infection","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025031817142783700_jiaf102-B5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","article-title":"Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment","volume":"59","author":"Seto","year":"2013","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/jvh.13722","article-title":"Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients","volume":"29","author":"Chu","year":"2022","journal-title":"J Viral Hepat"},{"key":"2025031817142783700_jiaf102-B7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/cpt.3287","article-title":"Optimal treatment based on interferon no longer makes clinical cure of chronic hepatitis B far away","volume":"116","author":"Li","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2025031817142783700_jiaf102-B8","doi-asserted-by":"crossref","first-page":"997608","DOI":"10.3389\/fimmu.2022.997608","article-title":"Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"2025031817142783700_jiaf102-B9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","article-title":"Cloning and characterization of two human polyspecific organic cation transporters","volume":"16","author":"Gorboulev","year":"1997","journal-title":"DNA Cell Biol"},{"key":"2025031817142783700_jiaf102-B10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41594-023-01017-4","article-title":"Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2","volume":"30","author":"Suo","year":"2023","journal-title":"Nat Struct Mol Biol"},{"key":"2025031817142783700_jiaf102-B11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1124\/mol.51.6.913","article-title":"Cloning and functional expression of a human liver organic cation transporter","volume":"51","author":"Zhang","year":"1997","journal-title":"Mol Pharmacol"},{"key":"2025031817142783700_jiaf102-B12","doi-asserted-by":"crossref","first-page":"9983","DOI":"10.1073\/pnas.1314939111","article-title":"OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin","volume":"111","author":"Chen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025031817142783700_jiaf102-B13","doi-asserted-by":"crossref","first-page":"e2002907","DOI":"10.1371\/journal.pbio.2002907","article-title":"Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content","volume":"16","author":"Liang","year":"2018","journal-title":"PLoS Biol"},{"key":"2025031817142783700_jiaf102-B14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3350\/cmh.2022.0422","article-title":"Chronic hepatitis B with concurrent metabolic dysfunction\u2013associated fatty liver disease: challenges and perspectives","volume":"29","author":"Huang","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2025031817142783700_jiaf102-B15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion","volume":"22","author":"Huang","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025031817142783700_jiaf102-B16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3350\/cmh.2023.0004","article-title":"Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis","volume":"29","author":"Wong","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2025031817142783700_jiaf102-B18","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1124\/dmd.108.020826","article-title":"Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection","volume":"36","author":"Jung","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"2025031817142783700_jiaf102-B19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 update)","volume":"5","author":"Hou","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"2025031817142783700_jiaf102-B20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2022.02.016","article-title":"Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection","volume":"77","author":"Montanari","year":"2022","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B21","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1136\/gutjnl-2020-323665","article-title":"Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target","volume":"72","author":"Verrier","year":"2022","journal-title":"Gut"},{"key":"2025031817142783700_jiaf102-B22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jhep.2023.09.039","article-title":"Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-\u03b1-treated patients with chronic hepatitis B","volume":"80","author":"Guan","year":"2024","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2024.05.016","article-title":"Helicases DDX5 and DDX17 promote heterogeneity in HBV transcription termination in infected human hepatocytes","volume":"81","author":"Chapus","year":"2024","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2021.02.009","article-title":"Translatomic profiling reveals novel self-restricting virus\u2013host interactions during HBV infection","volume":"75","author":"Yuan","year":"2021","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41421-021-00337-3","article-title":"Multiomics interrogation into HBV (hepatitis B virus)\u2013host interaction reveals novel coding potential in human genome, and identifies canonical and non-canonical proteins as host restriction factors against HBV","volume":"7","author":"Yuan","year":"2021","journal-title":"Cell Discov"},{"key":"2025031817142783700_jiaf102-B27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/jpet.105.099929","article-title":"The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha","volume":"317","author":"Saborowski","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2025031817142783700_jiaf102-B28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.113.206359","article-title":"Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene","volume":"347","author":"O\u2019Brien","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2025031817142783700_jiaf102-B29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.cr.7290187","article-title":"LRH-1\/hB1F and HNF1 synergistically up-regulate hepatitis B virus gene transcription and DNA replication","volume":"13","author":"Cai","year":"2003","journal-title":"Cell Res"},{"key":"2025031817142783700_jiaf102-B30","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jhep.2021.06.038","article-title":"Novel function of SART1 in HNF4\u03b1 transcriptional regulation contributes to its antiviral role during HBV infection","volume":"75","author":"Teng","year":"2021","journal-title":"J Hepatol"},{"key":"2025031817142783700_jiaf102-B31","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2011.12.045","article-title":"Estrogen receptor \u03b1 represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4\u03b1","volume":"142","author":"Wang","year":"2012","journal-title":"Gastroenterology"},{"key":"2025031817142783700_jiaf102-B32","first-page":"314","article-title":"Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure","volume":"11","author":"Gan","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"2025031817142783700_jiaf102-B33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/gm298","article-title":"DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma","volume":"3","author":"Schaeffeler","year":"2011","journal-title":"Genome Med"},{"key":"2025031817142783700_jiaf102-B34","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1128\/JVI.02280-09","article-title":"Hepatitis B virus replication induces methylation of both host and viral DNA","volume":"84","author":"Vivekanandan","year":"2010","journal-title":"J Virol"},{"key":"2025031817142783700_jiaf102-B35","article-title":"The Everest Project's 5-year update: efficacy of PegIFN\u03b1 therapy in NA-suppressed HBeAg negative CHB [abstract O-0161]","author":"Xie","year":"2024","journal-title":"Asian Pacific Association for the Study of the Liver, Kyoto, Japan, 27\u201331 March"},{"key":"2025031817142783700_jiaf102-B36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ajhg.2017.08.008","article-title":"Fine mapping and functional analysis reveal a role of SLC22A1 in acylcarnitine transport","volume":"101","author":"Kim","year":"2017","journal-title":"Am J Hum Genet"},{"key":"2025031817142783700_jiaf102-B37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.bjp.0702065","article-title":"Catecholamine transport by the organic cation transporter type 1 (OCT1)","volume":"125","author":"Breidert","year":"1998","journal-title":"Br J Pharmacol"},{"key":"2025031817142783700_jiaf102-B38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.14218\/JCTH.2024.00051","article-title":"Dopamine inhibits the expression of hepatitis B virus surface and e antigens by activating the JAK\/STAT pathway and upregulating interferon-stimulated gene 15 expression","volume":"12","author":"Liu","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"2025031817142783700_jiaf102-B39","article-title":"Thiamine appears beneficial in chronic active hepatitis B virus (HBV) infection","volume-title":"Inpharma Wkly","author":"Wallace","year":"2001"},{"key":"2025031817142783700_jiaf102-B40","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1572-0241.2001.03635.x","article-title":"Thiamine treatment of chronic hepatitis B infection","volume":"96","author":"Wallace","year":"2001","journal-title":"Am J Gastroenterol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf102\/62174663\/jiaf102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf102\/62174663\/jiaf102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:14:59Z","timestamp":1742318099000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiaf102\/8042865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf102","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"article-number":"jiaf102"}}